We are live on
!
Find out more
APM
Avidity Partners Management Portfolio holdings
AUM
$624M
Turnover
44.83%
1-Year Est. Return
250.2%
This Fund
S&P 500
This Quarter
Est. Return
-4.8%
1 Year Est. Return
+250.2%
3 Year Est. Return
+491.63%
5 Year Est. Return
+985.37%
10 Year Est. Return
–
AUM
$724M
AUM Growth
+$565M
(+356%)
Cap. Flow
+$604M
Cap. Flow
% of AUM
83.45%
Top 10 Holdings %
Top 10 Hldgs %
43.31%
Holding
66
New
33
Increased
17
Reduced
2
Closed
14
Avg Time Held Equity + Options
0.1
years
Top 10 Avg Time Held Equity + Options
0.1
years
Top 20 Avg Time Held Equity + Options
0.1
years
Avg Time Held Equity only
0.1
years
Top 10 Avg Time Held Equity only
0.1
years
Top 20 Avg Time Held Equity only
0.1
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$64.2M |
| 2 |
Merck
MRK
|
+$40.5M |
| 3 |
McKesson
MCK
|
+$35.6M |
| 4 |
AbbVie
ABBV
|
+$32.6M |
| 5 |
Cardinal Health
CAH
|
+$26.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Baxter International
BAX
|
+$13.8M |
| 2 |
HCA Healthcare
HCA
|
+$9.27M |
| 3 |
Zimmer Biomet
ZBH
|
+$8.16M |
| 4 |
Edwards Lifesciences
EW
|
+$6.3M |
| 5 |
Axonics, Inc. Common Stock
AXNX
|
+$5.76M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 96.4% |
| 2 | Miscellaneous | 3.6% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
SGEN
1
DELISTED
Seagen Inc. Common Stock
SGEN
| $66.9M | 9.25% |
+580,000
| New | +$64.2M |
2020 Q1
0 quarters
|
|
|
2
Merck
MRK
$358B
| $37.9M | 5.23% |
+515,616
| New | +$40.5M |
2020 Q1
0 quarters
|
|
|
3
AbbVie
ABBV
$501B
| $36.3M | 5.02% |
477,000
+383,000
| +407% | +$32.6M |
2019 Q4
1 quarter
|
|
|
4
McKesson
MCK
$116B
| $32.9M | 4.54% |
+243,000
| New | +$35.6M |
2020 Q1
0 quarters
|
|
5
BioMarin Pharmaceuticals
BMRN
$10.8B
| $25.5M | 3.53% |
+302,000
| New | +$26M |
2020 Q1
0 quarters
|
|
6
Regeneron Pharmaceuticals
REGN
$82B
| $24.4M | 3.37% |
+50,000
| New | +$20.6M |
2020 Q1
0 quarters
|
|
|
7
Cardinal Health
CAH
$58.7B
| $24.2M | 3.35% |
+505,000
| New | +$26.2M |
2020 Q1
0 quarters
|
|
|
MRTX
8
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $22.7M | 3.13% |
295,000
+231,000
| +361% | +$20.7M |
2019 Q4
1 quarter
|
|
9
DELISTED
CATALENT, INC.
CTLT
| $21.4M | 2.95% |
411,000
+319,000
| +347% | +$17.4M |
2019 Q4
1 quarter
|
|
|
MNTA
10
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $21.2M | 2.93% |
780,000
+580,000
| +290% | +$16.1M |
2019 Q4
1 quarter
|
|
11
Biogen
BIIB
$34.8B
| $19.6M | 2.71% |
+62,000
| New | +$18.8M |
2020 Q1
0 quarters
|
|
12
Exelixis
EXEL
$15.6B
| $18.7M | 2.58% |
+1,086,000
| New | +$19.9M |
2020 Q1
0 quarters
|
|
13
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $18.4M | 2.54% |
+540,000
| New | +$24.7M |
2020 Q1
0 quarters
|
|
14
Alector
ALEC
$213M
| $17.2M | 2.38% |
+714,000
| New | +$18.2M |
2020 Q1
0 quarters
|
|
15
Aurinia Pharmaceuticals
AUPH
$2.23B
| $17.2M | 2.37% |
1,182,000
+950,000
| +409% | +$16.8M |
2019 Q4
1 quarter
|
|
16
CVS Health
CVS
$118B
| $16.4M | 2.27% |
+277,000
| New | +$18.5M |
2020 Q1
0 quarters
|
|
17
Acadia Pharmaceuticals
ACAD
$3.4B
| $15.1M | 2.08% |
357,000
+303,000
| +561% | +$12.5M |
2019 Q4
1 quarter
|
|
18
Gilead Sciences
GILD
$195B
| $15M | 2.07% |
+200,000
| New | +$13.8M |
2020 Q1
0 quarters
|
|
|
XLRN
19
DELISTED
Acceleron Pharma
XLRN
| $14.9M | 2.06% |
+166,000
| New | +$12.9M |
2020 Q1
0 quarters
|
|
|
ALXN
20
DELISTED
Alexion Pharmaceuticals
ALXN
| $14.4M | 1.99% |
+160,000
| New | +$15.7M |
2020 Q1
0 quarters
|
|
|
SGEN
21
CALL
DELISTED
Seagen Inc. Common Stock
SGEN
| $13.6M | 1.88% |
+117,700
| New | +$13M |
2020 Q1
0 quarters
|
|
22
DELISTED
Dynavax Technologies
DVAX
| $13.5M | 1.87% |
3,824,000
+3,044,000
| +390% | +$14.1M |
2019 Q4
1 quarter
|
|
|
KDMN
23
DELISTED
Kadmon Holdings, Inc.
KDMN
| $11.8M | 1.64% |
2,828,000
+1,998,000
| +241% | +$8.6M |
2019 Q4
1 quarter
|
|
24
Axsome Therapeutics
AXSM
$8.47B
| $11.6M | 1.6% |
+197,000
| New | +$16.1M |
2020 Q1
0 quarters
|
|
25
Cigna
CI
$79B
| $11.5M | 1.59% |
65,000
+35,000
| +117% | +$6.79M |
2019 Q4
1 quarter
|
|
Similar funds
ANB
RIP
TAM
B
PWS
LWP
FGA
BVC
Avidity Partners Management's Q1 2020 Portfolio in Review
As of Q1 2020, Avidity Partners Management held 66 positions worth $724M, up 356% from $159M the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Avidity Partners Management deployed $604M of net new capital in Q1 2020, opening 33 new positions and adding to 17 existing holdings. Its largest new stake was Seagen Inc. Common Stock: 580,000 shares worth $66.9M.
By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 100% a quarter earlier, followed by Miscellaneous.
On the sell side, the largest reduction was Collegium Pharmaceutical, an estimated $3.36M trimmed.
- Avidity Partners Management's largest Q1 2020 buy was Seagen Inc. Common Stock: 580,000 shares worth $66.9M.
- Avidity Partners Management added most to AbbVie in Q1 2020, an estimated $32.6M increase.
- Avidity Partners Management's biggest Q1 2020 reduction was Collegium Pharmaceutical, cutting an estimated $3.36M.
- Avidity Partners Management fully exited Baxter International in Q1 2020, selling an estimated $13.8M.
- Avidity Partners Management's ten largest holdings make up 43% of its $724M portfolio in Q1 2020.
- Avidity Partners Management opened 33 new positions and closed 14 in Q1 2020.
- Avidity Partners Management's portfolio value rose 356% quarter-over-quarter to $724M.
Based on Avidity Partners Management's 13F filing for Q1 2020, filed 15 May 2020.